AR061785A1 - Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activas - Google Patents
Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activasInfo
- Publication number
- AR061785A1 AR061785A1 ARP070102249A ARP070102249A AR061785A1 AR 061785 A1 AR061785 A1 AR 061785A1 AR P070102249 A ARP070102249 A AR P070102249A AR P070102249 A ARP070102249 A AR P070102249A AR 061785 A1 AR061785 A1 AR 061785A1
- Authority
- AR
- Argentina
- Prior art keywords
- nanoparticles
- administration
- active molecules
- quantian
- hialuronan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Optics & Photonics (AREA)
- Ophthalmology & Optometry (AREA)
- Nanotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Sistema de nanopartículas util para la administracion de moléculas farmacologicamente activas, y especialmente para transfectar polinucleotidos dentro de células. Comprende nanopartículas de quitosano de bajo peso molecular e hialuronano. Composiciones farmacéuticas y cosméticas que lo contienen y uso del sistema para terapia génica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06380132A EP1859792A1 (en) | 2006-05-24 | 2006-05-24 | Nanoparticles of chitosan and hyaluronan for the administration of active molecules |
EP06124177 | 2006-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061785A1 true AR061785A1 (es) | 2008-09-24 |
Family
ID=38577658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102249A AR061785A1 (es) | 2006-05-24 | 2007-05-24 | Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activas |
Country Status (8)
Country | Link |
---|---|
US (1) | US20110142890A1 (es) |
EP (1) | EP2026772A1 (es) |
JP (1) | JP2009537604A (es) |
KR (1) | KR20090031861A (es) |
AR (1) | AR061785A1 (es) |
CA (1) | CA2652530A1 (es) |
IL (1) | IL195316A0 (es) |
WO (1) | WO2007135164A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110033547A1 (en) * | 2007-07-06 | 2011-02-10 | Aarhus Universitet | Dehydrated chitosan nanoparticles |
WO2009035438A1 (en) * | 2007-09-13 | 2009-03-19 | Janos Borbely | Polymeric nanoparticles by ion-ion interactions |
ES2345806B1 (es) * | 2009-03-30 | 2011-07-22 | Universidad De Santiago De Compostela | Sistemas nanoparticulares elaborados a base de polimeros anionicos para administrar moleculas bioactivas para uso cosmetico. |
JP5804453B2 (ja) * | 2009-05-14 | 2015-11-04 | 国立大学法人 東京大学 | 結晶性ポリオール微粒子及びその調製方法 |
EP2266546A1 (en) | 2009-06-08 | 2010-12-29 | Advancell Advanced in Vitro Cell Technologies,S.A. | Process for the preparation of colloidal systems for the delivery of active compounds |
ES2351756B1 (es) | 2009-07-28 | 2011-10-05 | Universidad Del Pais Vasco | Nanopartículas lipídicas para terapia génica. |
JP5785168B2 (ja) | 2009-07-31 | 2015-09-24 | エスリス ゲーエムベーハーethris GmbH | タンパク質発現用未修飾および修飾ヌクレオチドの組み合わせを有するrna |
KR101138258B1 (ko) * | 2009-12-09 | 2012-04-24 | (주)바이오제닉스 | 올리고머 복합체의 형성을 통한 난/불용성 활성물질의 가용화 방법 |
FR2963351B1 (fr) * | 2010-07-30 | 2013-03-08 | Univ Claude Bernard Lyon | Particules formees d'un complexe polyelectrolyte de chitosane et d'un polysaccharide anionique, presentant une stabilite amelioree |
GB201017889D0 (en) * | 2010-10-22 | 2010-12-01 | Univ Dublin | A polymeric nanoparticle |
US8897536B2 (en) * | 2011-04-24 | 2014-11-25 | Universidade Da Coruna. Otri | Molecular block-matching method for gel image analysis |
US8968790B2 (en) | 2011-12-09 | 2015-03-03 | Shaker A. Mousa | Nanoformulation of vitamin D derivatives and/or vitamin D metabolites |
WO2013166616A1 (es) * | 2012-05-11 | 2013-11-14 | Universidad Austral De Chile | Biomaterial que comprende quitosano y al menos glicosaminoglicano |
JP6120397B2 (ja) * | 2012-10-11 | 2017-04-26 | ポーラ化成工業株式会社 | キトサン及びヒアルロナンを含むナノ粒子の製造方法 |
EP3016634A2 (en) * | 2013-07-05 | 2016-05-11 | Therakine Biodelivery GmbH | Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition |
WO2016066864A1 (es) | 2014-10-30 | 2016-05-06 | Innovaciones Fisicas Y Quimicas Sostenibles, S.L. | Nanopartículas para la liberación controlada de ingredientes activos |
WO2016127251A1 (en) * | 2015-02-09 | 2016-08-18 | Polyvalor, Société En Commandite (S.E.C.) | Coated chitosan-based polyplex for delivery of nucleic acids |
SG11201903443QA (en) | 2016-10-17 | 2019-05-30 | Pola Chem Ind Inc | Composite particles including anionic polymer and cationic polymer or peptide, and method for producing composite particles |
WO2018143493A1 (ko) * | 2017-02-03 | 2018-08-09 | 서강대학교 산학협력단 | 아토피 질환 치료용 siRNA 하이드로젤 기반 나노입자 및 이의 제조방법 |
US20210401934A1 (en) * | 2017-04-10 | 2021-12-30 | King Abdulaziz City For Science And Technology | Protein functionalized hyaluronic acid coated chitosan nanoparticle and method of preparation |
WO2021033725A1 (ja) * | 2019-08-21 | 2021-02-25 | 株式会社 資生堂 | 化粧料 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998017320A1 (en) * | 1991-07-03 | 1998-04-30 | Hyal Pharmaceutical Corporation | Use of hyaluronan in gene therapy |
US20010053359A1 (en) * | 1994-07-26 | 2001-12-20 | Peter Watts | Drug delivery composition for the nasal administration of antiviral agents |
US6184037B1 (en) * | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
FR2777193B1 (fr) * | 1998-04-14 | 2001-06-08 | Coletica | Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie |
DE10050870A1 (de) * | 2000-10-11 | 2002-08-01 | Knoell Hans Forschung Ev | Biokompatibles Verbundmaterial für medizinische Anwendungen |
FR2841137B1 (fr) * | 2002-06-20 | 2004-08-13 | Bioalliance Pharma | Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement |
ES2226567B1 (es) * | 2003-06-20 | 2006-07-01 | Universidad De Santiago De Compostela | Nanoparticulas de acido hialuronico. |
-
2007
- 2007-05-23 JP JP2009511514A patent/JP2009537604A/ja active Pending
- 2007-05-23 WO PCT/EP2007/054983 patent/WO2007135164A1/en active Application Filing
- 2007-05-23 US US12/301,835 patent/US20110142890A1/en not_active Abandoned
- 2007-05-23 EP EP07729421A patent/EP2026772A1/en not_active Withdrawn
- 2007-05-23 CA CA002652530A patent/CA2652530A1/en not_active Abandoned
- 2007-05-23 KR KR1020087029425A patent/KR20090031861A/ko not_active Application Discontinuation
- 2007-05-24 AR ARP070102249A patent/AR061785A1/es unknown
-
2008
- 2008-11-16 IL IL195316A patent/IL195316A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20090031861A (ko) | 2009-03-30 |
WO2007135164A1 (en) | 2007-11-29 |
US20110142890A1 (en) | 2011-06-16 |
IL195316A0 (en) | 2009-08-03 |
JP2009537604A (ja) | 2009-10-29 |
CA2652530A1 (en) | 2007-11-29 |
EP2026772A1 (en) | 2009-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061785A1 (es) | Nanoparticulas de quitosano e hialuronano para la administracion de moleculas activas | |
MX2021005389A (es) | Formulaciones de nanoparticulas lipidicas. | |
BR112015015319A2 (pt) | composições de nanopartícula de albumina e paclitaxel | |
BR112014027834A2 (pt) | composições de nanopartícula lipídica para entrega de oligonucleotídeos antissenso | |
BR112015011118A2 (pt) | conjugado; composição farmacêutica; e uso de um ou mais dos conjugados | |
CL2008001124A1 (es) | Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer. | |
BR112018003316A2 (pt) | compostos e métodos para entrega transmembrana de moléculas | |
NZ595372A (en) | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | |
BRPI0607549A2 (pt) | sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos | |
BR112013003825A2 (pt) | conjugados, partículas, composições e métodos relacionados | |
BR112012026213A8 (pt) | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa | |
BR112015007985A2 (pt) | compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados | |
BR112012016021A8 (pt) | Formulações estáveis para liofilização de partículas terapêuticas | |
BR112016022553A2 (pt) | Compostos e métodos para entrega transmembrana de moléculas? | |
BR112012026801B8 (pt) | conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento | |
BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
BR112018002342A2 (pt) | polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos | |
BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
BR112012023638A2 (pt) | Sistema de entrega, composição cosmética, farmacêutica e/ou alimentar e uso da composição cosmética, farmacêutica e/ou alimentar | |
WO2008129106A3 (es) | Nanopartículas que comprenden una ciclodextrina y una molécula biológicamente activa y sus aplicaciones | |
WO2011079279A3 (en) | Nanoconjugates and nanoconjugate formulations | |
CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
PE20081881A1 (es) | Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos | |
BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
BR112015008954A2 (pt) | composições de ciclodextrina alquilatada e processos para preparação e uso das mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |